UBS Group
INKT icon

UBS Group’s MiNK Therapeutics INKT Stock Holding History

UBS Group’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160K Buy
15,202
+5,654
+59% +$63K ﹤0.01% 6760
2025
Q4 		$106K Buy
9,548
+3,900
+69% +$50.4K ﹤0.01% 6882
2025
Q3 		$79.1K Buy
5,648
+5,364
+1,889% +$85.9K ﹤0.01% 7267
2025
Q2 		$2.1K Hold
284
– – ﹤0.01% 9519
2025
Q1 		$2.45K Sell
284
-1
-0.4% -$9 ﹤0.01% 9329
2024
Q4 		$1.98K Sell
285
-336
-54% -$2.29K ﹤0.01% 9127
2024
Q3 		$4.66K Buy
621
+299
+93% +$2.54K ﹤0.01% 8133
2024
Q2 		$3.06K Sell
322
-1
-0.3% -$10 ﹤0.01% 8263
2024
Q1 		$2.94K Sell
323
-182
-36% -$1.69K ﹤0.01% 7805
2023
Q4 		$5.4K Buy
505
+150
+42% +$1.57K ﹤0.01% 7788
2023
Q3 		$3.9K Buy
355
+40
+13% +$651 ﹤0.01% 7501
2023
Q2 		$6.62K Buy
315
+130
+70% +$2.6K ﹤0.01% 7351
2023
Q1 		$3.51K Sell
185
-65
-26% -$1.41K ﹤0.01% 8313
2022
Q4 		$6.54K Buy
250
+224
+862% +$5.26K ﹤0.01% 9024
2022
Q3 		$1K Hold
26
– – ﹤0.01% 9970
2022
Q2 		$0 Sell
26
-510
-95% -$9.61K ﹤0.01% 10606
2022
Q1 		$12K Buy
536
+143
+36% +$4.3K ﹤0.01% 8183
2021
Q4 		$18K Buy
+393
New +$46.7K ﹤0.01% 7975

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's INKT Position: Q1 2026 in Review

UBS Group increased its MiNK Therapeutics (INKT) stake by 59% in Q1 2026, buying an estimated $63K and bringing the position to 15,202 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #6760.

UBS Group first reported a position in INKT in Q4 2021 and has held it in 18 quarters since. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • UBS Group held 15,202 shares of MiNK Therapeutics worth $160K as of Q1 2026.
  • UBS Group bought 5,654 MiNK Therapeutics shares in Q1 2026, an estimated $63K.
  • MiNK Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6760 holding.
  • UBS Group first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.